Bristol-Myers Squibb: Carcinoma, Hepatocellular trials

The registry lists 19 Carcinoma, Hepatocellular studies with Bristol-Myers Squibb as lead sponsor. 3 are open to participants now and 7 have results posted.

Phase 1 9Phase 2 8Phase 3 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)RecruitingNCT07679061
• A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingNCT07291076Phase 1/2
• Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCCRecruitingNCT06726161Phase 1/2
• A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCompletedNCT05337137Phase 1/2Results posted
• A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsCompletedNCT04567615Phase 2Results posted
• A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02859324Phase 1/2Results posted
• A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver CancerTerminatedNCT02828124Phase 1/2Results posted
• An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02576509Phase 3Results posted
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results posted
• A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerCompletedNCT00355238Phase 2Results posted
• A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab TherapyCompletedNCT04161911
• A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedNCT04039607Phase 3
• A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationActive, not recruitingNCT03383458Phase 3
• Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver CancerTerminatedNCT02323906Phase 1
• Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)CompletedNCT01540461Phase 1
• Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib TreatmentTerminatedNCT01108705Phase 3
• Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCCCompletedNCT00908752Phase 3
• First Line Hepato Cellular Carcinoma (HCC)CompletedNCT00858871Phase 3
• A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver DysfunctionCompletedNCT00437424Phase 1